DURGA-1

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Near Add Your Location

Sorting 33 by

Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
  • Show Principal Investigator
Sarah Cannon Research Institute
TriStar Centennial Medical Center
Nashville, TN
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Stony Brook University Hospital
Stony Brook, NY
  • Accepting patients
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
Henry Ford Hospital
Detroit, MI
  • Accepting patients
Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
  • Accepting patients
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
Swedish Cancer Institute
Swedish Edmonds Campus
Edmonds, WA
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.